Journals / Gazi Üniversitesi Diş Hekimliği Fakültesi Dergisi / 2010 / Cilt: 27 - Sayı: 2

Opg/rank/ranklaxis in periodontology

Opg/rank/rankl’ın periodontolojideki yeri

Pages
137–144
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Biologic approaches targeting RANKRANKL- OPG axis seem to be a new concept over the pathogenesis of periodontal lesions and future therapeutic options.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Periodontitis is an infectious disease characterized by inflammation in gingiva and rezorption of alveolar bone.
📊
Key Findings & Data:Bacterial factors and immune system of the host- mediated proinflammatory molecules- are involed in this inflammatory process.
💡
Conclusion & Impact:Biologic approaches targeting RANKRANKL- OPG axis seem to be a new concept over the pathogenesis of periodontal lesions and future therapeutic options.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Periodontitis is an infectious disease characterized by inflammation in gingiva and rezorption of alveolar bone. Bacterial factors and immune system of the host- mediated proinflammatory molecules- are involed in this inflammatory process. Because of involving both immunology and bone metabolism, the etiology of periodontitis is being examined in a new interdisciplinary field called “osteoimmunology”. Recently investigated molecules that are thought to be responsible for bone loss, are OPG, RANKL, RANK. RANKL, its receptor RANK–stimulating osteoclast maturation- and decoy receptor OPG –inhibiting RANKL to induce osteoclastogenesis- are key molecules that regulate osteoclast recruitment and function. The axis of these three molecules are critical for pathologic lesions in chronic inflammation, bone and vascular pathologies. RANKL levels in gingival tissue and gingival crevicular fluid of the patients with periodontitis are higher than those of periodontally healthy people. Therefore destruction of the periodontal tissues can be improved by blocking RANKL expression and function. Biologic approaches targeting RANKRANKL- OPG axis seem to be a new concept over the pathogenesis of periodontal lesions and future therapeutic options.

Özet

Periodontitis gingival inflamasyon ve alveoler kemik kaybı ile karakterize infeksiyöz bir hastalıktır. Bakteriyel faktörler ve proinflamatuvar molekülleri aktive eden konağın immün cevabı inflamasyonun gelişiminde en önemli rolü oynamaktadır. İmmünoloji ve kemik metabolizmasının birlikte yer almasından dolayı periodontitis etiyolojisi yeni bir interdisipliner alan olan “osteoimmünoloji” başlığı altında incelenmeye başlanmıştır. OPG,RANKL ve RANK günümüzde kemik yıkımından sorumlu olduğu düşünülen moleküllerdir. RANKL, reseptörü olan ve osteoklast maturasyonunu stimüle eden RANK ile tuzak reseptör olup RANKL’ın osteoklastogenezisi indüklemesini engelleyen OPG osteoklast aktivasyonu ve fonksiyonunu düzenleyen anahtar üçlü olarak görülmektedirler. Bu üç molekülün düzeninin kronik inflamasyondaki patolojik lezyonlarda ve kemik-damar patolojilerinde önemli olduğu görülmüştür. Periodontitisli hastaların gingival dokuları ve diş eti oluğu sıvısında (DOS) sağlıklı bireylere göre yüksek seviyede RANKL olduğu saptanmıştır. Periodontal dokulardaki kaybın RANKL ekspresyonu ve fonksiyonunun bloke edilerek engellenebileceği düşünülmektedir. RANK-RANKL-OPG üçlüsünü hedefleyen biyolojik yaklaşımların peridontal hastalıkların patogenezi ve gelecekteki terapötik uygulamalarda önem kazanması için çalışmalar yapılmaktadır.

🔖

Cite This Article

BABÜR, C., ÖZCAN, G. (2022). Opg/rank/ranklaxis in periodontology. Gazi Üniversitesi Diş Hekimliği Fakültesi Dergisi, Cilt: 27 - Sayı: 2, 137–144. https://ajindex.com/articles/521543

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, TometskoME, Roux ER, TeepeMC, DuBose RF, Cosman D, Galibert L.Ahomologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179, 1997
  2. Arron JR, ChoiY. Bone versus immune system. Nature 408: 535- 536, 2000
  3. Bar-Shavit Z. The osteoclast: a multinucleated, hematopoieticorigin, bone-resorbing osteoimmune cell. J Cell Biochem 102: 1130-1139, 2007
  4. Baud'huin M, Lamoureux F, Duplomb L, Redini F, Heymann D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 64: 2334-2350, 2007
  5. Bickel M, Axtelius B, Solioz C, Attstrom R. Cytokine gene expression in chronic periodontitis. J Clin Periodontol 28: 840-847, 2001
  6. Blair JM, Zheng Y, Dunstan CR. RANK ligand. Int J Biochem Cell Biol 39: 1077-1081, 2007
  7. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3: 41-49, 2006
  8. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Toz H, Atilla G, Hughes FJ, and Belibasakis GN. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol 34: 370-376, 2007
  9. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Toz H, Berdeli A, Atilla G, McKay IJ, Hughes FJ, Belibasakis GN. Differential expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin mRNA in periodontal diseases. J Periodontal Res 42: 287-293, 2007
  10. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 423: 337-342, 2003
  11. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7: 2977-2983, 2001
  12. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, XuW, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268, 1998
  13. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145: 527-538, 1999
  14. Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, Ahern MJ, Haynes D. Receptor activator NF kappaB ligand (RANKL)